• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by E Thomas Darcy

    2/24/21 8:02:37 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care
    Get the next $SNSS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    DARCY THOMAS E

    (Last) (First) (Middle)
    C/O VIRACTA THERAPEUTICS, INC.
    2533 S COAST HWY 101, SUITE 210

    (Street)
    CARDIFF CA 92007

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/24/2021
    3. Issuer Name and Ticker or Trading Symbol
    SUNESIS PHARMACEUTICALS INC [ VIRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities beneficially owned Exhibit 24: Power of Attorney
    No securities are beneficially owned.
    /s/ Michael Mueller, as Attorney-in-Fact 02/24/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SNSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by J. Barry Simon

    3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

    3/4/21 5:46:22 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form 3 filed by Stephen Rubino

    3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

    3/4/21 5:42:13 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

    3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)

    2/25/21 6:09:20 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    $SNSS
    Financials

    Live finance-specific insights

    View All

    Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

    Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

    11/30/20 7:30:00 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    $SNSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed

    SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

    3/10/21 9:40:22 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

    3/8/21 5:05:56 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

    3/5/21 1:30:27 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    $SNSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

    SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

    2/16/21 8:00:00 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

    SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

    2/11/21 4:05:00 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

    SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

    12/7/20 8:30:00 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    $SNSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00

    3/1/21 8:39:16 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00

    2/23/21 5:59:10 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    $SNSS
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

    3/4/21 4:06:03 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K filed

    8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

    2/24/21 4:34:51 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care

    SEC Form 10-K filed

    10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

    2/24/21 6:06:16 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care